Clinical trials: High-risk Breast Cancer
Breast-Conserving Surgery
Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision
This clinical trial evaluates the safety and efficacy of High Purity Type I Collagen scaffold for breast volume restoration following breast-conserving surgery (BCS).
- Trial name
- NCT07219316
- Testing
- High Purity Type I Collagen Scaffold (Regenerative Matrix)
- Where
- 2 sites in India
- Volunteers
- 40 people
- Sponsor
- Adichunchanagiri Institute of Medical Sciences, B G Nagara
Metastatic Breast Cancer, FGFR 1 High Amplification
A Study of TAS-120 in Patients With Metastatic Breast Cancer
The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant.
- Conditions
- Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
- Trial name
- NCT04024436
- Testing
- Futibatinib, Futibatinib plus Fulvestrant
- Where
- 37 sites in United States, Canada and 5 more
- Volunteers
- 64 people
- Sponsor
- Taiho Oncology, Inc.
Breast Cancer
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her breast and decreasing the…
- Trial name
- NCT00462865
- Testing
- Gemcitabine and Capecitabine and Avastin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Breast Cancer
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer
This randomized phase II trial is studying how well genistein works in preventing breast cancer in women at high risk for breast cancer.
- Trial name
- NCT00290758
- Testing
- genistein, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
High Dose Vitamin D vs Standard Dose Vitamin D Study
This study is being done to look at the difference, if there is a difference between two different doses of Vitamin D and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications…
- Trial name
- NCT01988090
- Testing
- 800 IU Vitamin D Supplement, 50,000 IU Vitamin D supplement
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Mothaffar Rimawi
Breast Cancer
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D…
- Trial name
- VITAL (NCT00867217)
- Testing
- High Dose Vitamin D, Standard Dose Vitamin D3, Letrozole 2.5mg
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- Qamar Khan
Breast Cancer
Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk
This study seeks to develop an explanatory framework for breast MRI utilization to inform future interventions. The Health Services Utilization Model (HSUM) will guide the selection of specific participant-level factors for…
- Trial name
- B-SUPER (NCT04257474)
- Testing
- Self-Report Survey, Qualitative Interviews
- Where
- 2 sites in United States
- Volunteers
- 265 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia
Ruxolitinib for Premalignant Breast Disease
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for…
- Conditions
- Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
- Trial name
- TBCRC042 (NCT02928978)
- Testing
- Ruxolitinib
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Julie Nangia
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Invasive Breast Cancer
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone…
- Trial name
- CemiHALT (NCT04243616)
- Testing
- Cemiplimab, Paclitaxel, Carboplatin (not mandatory)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical College of Wisconsin
Triple Negative Breast Neoplasms
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase…
- Trial name
- NCT04489940
- Testing
- Bintrafusp alfa
- Where
- 45 sites in United States, Belgium and 4 more
- Volunteers
- 11 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
BRCA1 Mutation, Breast Cancer
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women with BRCA1 mutations.
- Trial name
- NCT00700778
- Testing
- recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method
- Where
- 3 sites in United States, Austria
- Volunteers
- 2 people
- Sponsor
- Fox Chase Cancer Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT03323658
- Testing
- Bexarotene, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
RATIONALE: Giving chemotherapy, such as fludarabine and melphalan, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells.
- Trial name
- NCT00074269
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Breast Cancer
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
This was an open label, multi-center protocol for U.S. patients enrolled in the study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast…
- Trial name
- EarLEE-1 (NCT03078751)
- Testing
- Ribociclib, Adjuvant endocrine therapy
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Invasive Ductal
Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer
The purpose of the study is to evaluate the efficacy of a dedicated Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) unit in ablating breast cancer by comparing MR imaging and pathologic specimen after…
- Trial name
- NCT03560102
- Testing
- Philips Sonalleve® MR-HIFU Breast Therapy System
- Where
- Switzerland
- Volunteers
- 1 people
- Sponsor
- Kantonsspital Winterthur KSW
Breast Cancer
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
This phase II trial is studying how well acolbifene works in preventing cancer in premenopausal women at high risk of breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming.
- Trial name
- NCT00853996
- Testing
- acolbifene hydrochloride
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Breast Cancer
Community Hospital Identification of High CV Risk Patients During Cancer Treatment
The overall of this proposal is to test in community hospitals the utility of a 10-min magnetic resonance imaging (MRI) scan protocol combined with proprietary image analysis algorithms for detecting early cardiovascular (CV)…
- Trial name
- CHI (NCT02566109)
- Testing
- Fast MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Triple Negative Breast Cancer
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03387085
- Testing
- Aldoxorubicin HCl, N-803, ETBX-011
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- ImmunityBio, Inc.
Breast Cancer
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have…
- Trial name
- NCT00005879
- Testing
- arzoxifene
- Where
- 2 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center